LB Pharmaceuticals Inc Common Stock LBRX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Direct Research And Development Expenses by Product | ||||||
| Bipolar Depression Programs | $3.01M— | —— | —— | —— | $0— | |
| Formulation And CMC | $2.33M— | —— | —— | —— | $653K+15.1% | |
| Preclinical And Other Direct Expenses | $501K— | —— | —— | —— | $0— | |
| Schizophrenia Programs | $5.81M— | —— | —— | —— | $1.26M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does LB Pharmaceuticals Inc Common Stock break its business down?
- LB Pharmaceuticals Inc Common Stock (LBRX) reports direct research and development expenses by product across 6 parts — Bipolar Depression Programs, Clinical Trial, Formulation And CMC, Preclinical And Other Direct Expenses and Preclinical. Each is extracted from the segment footnotes and tracked over time.
- Where does LB Pharmaceuticals Inc Common Stock's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in LB Pharmaceuticals Inc Common Stock's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.